Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion

NCT03981549 is registered in ClinicalTrials.gov with The Emmes Company, LLC as lead sponsor.

NCT NCT03981549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03981549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Randomized, Prospective, Double-masked, Sham-controlled Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Central Retinal Vein Occlusion
Lead sponsor
The Emmes Company, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
October 22, 2019
Completion date
November 9, 2023
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central retinal vein occlusion